Language selection

Search

Patent 1270759 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent: (11) CA 1270759
(21) Application Number: 1270759
(54) English Title: SOFT GELATIN CAPSULES AND PROCESS FOR MANUFACTURE
(54) French Title: CAPSULES DE GELATINE MOLLE, ET LEUR FABRICATION
Status: Expired and beyond the Period of Reversal
Bibliographic Data
(51) International Patent Classification (IPC):
  • A61K 09/66 (2006.01)
(72) Inventors :
  • BROX, WERNER (Germany)
  • GABLER, WILFRIED (Germany)
(73) Owners :
  • R.P. SCHERER CORPORATION
(71) Applicants :
  • R.P. SCHERER CORPORATION (United States of America)
(74) Agent: SMART & BIGGAR LP
(74) Associate agent:
(45) Issued: 1990-06-26
(22) Filed Date: 1986-02-18
Availability of licence: N/A
Dedicated to the Public: N/A
(25) Language of filing: English

Patent Cooperation Treaty (PCT): No

(30) Application Priority Data: None

Abstracts

English Abstract


ABSTRACT OF THE DISCLOSURE
Soft gelatin capsules with a gelatin shell, at
least one plasticizer and a capsule filling that
contains at least one pharmacologically-active
substance and a solvent containing at least 50% by
weight of a mixture of polyethylene glycol ethers
of tetrahydrofurfuryl alcohol having the formula I:
<IMG>
I,
where n = 1 to 6. The capsules must be dried for 5
to 10 days in manufacture.


Claims

Note: Claims are shown in the official language in which they were submitted.


-10-
I HEREBY CLAIM AS MY INVENTION:
1. Soft gelatin capsules with a gelatin
shell, at least one plasticizer and a capsule
filling that contains at least one
pharmacologically-active substance and a solvent,
characterized in that the solvent contains at least
50% by weight of a mixture of polyethylene glycol
ethers of tetrahydrofurfuryl alcohol having the
formula I:
<IMG>
I,
where n = 1 to 6.
2. Soft gelatin capsules according to claim
1, characterized in that n = 1 and 2.
3. Processes for the manufacture of soft
gelatin capsules with a gelatin shell, at least one
plasticizer and a capsule filling that contains at
least one pharmacologically-active substance and a
solvent, characterized in that at least 50% by
weight of a mixture of polyethylene glycol ethers
of tetrahydrofurfuryl alcohol having the formula I:
<IMG>

-11- 61368-773
I,
where n = 1 to 6, is used as the solvent,
encapsulated in a wet gelatin shell, and that the
capsules obtained are dried for 5 to 10 days.
4. Processes according to claim 3
characterized in that n = 1 and 2.
5. Use of mixtures of polyethylene glycol
ethers of tetrahydrofurfuryl alcohol having the
formula I as defined in claim 1 as solvents for active
materials in soft gelatin capsules.
6. Use according to claim 5 characterized in
that additional solvents are used.
7. Use according to claim 5 or 6
characterized in that polyethylenglycol is used as
an additional solvent.

Description

Note: Descriptions are shown in the official language in which they were submitted.


~ ~'7~ 59
BACKGROUND OF THE INVENTION
Field of the Invention
The present invention concerns soft
gelatin capsules with a gelatin shell, at least one
plasticizer, and a capsule filling which contains
at least one pharmacologically-active substance and
a solvent, as well as processes for their
manufacture.
Description of the Prior Art
Gelatin capsules, especially soft gelatin
capsules, have become increasingly important as a
form of medication since it became feasible, in the
1930's, to manufacture them by making and filling
the capsules in one operation. Compared to other
dosage forms, they show a number of advantages.
Thus, they are odorless and tasteless, they can be
taken easily and, owing to their swelling
capability~ and water solubility, the drugs are
readily liberated in the stomach. Numerous drugs
which, on account of their sensitivity to oxidation
and to light, their thermal stability or their
hygroscopicity, may not be processed into other
medicinal ~orms, can be encapsulated without
impairment of their function.
Soft gelatin capsules serve chiefly for
the containment of liquids, i.e. oily solutions,
suspensions or emulsions. Vegetable , animal and
mineral oils, liquid hydrocarbons, ethereal oils
and also polyethylene glycols are in use as
fillings. Fats and waxes are also applied or
admixed to increase the consistency.
Polyethylene glycols are superior to
other possible filling materials for 50ft gelatin

127~3~75~
capsules in a number of ways. In contrast to oily
liquids, polyethylene glycols are mixable with
water in all proportions.
At the same time, because polyethylene
5 glycols are able to dissolve many drugs which are
sparingly soluble or insoluble in water, the use of
polyethylene glycols, with such drugs, makes
possible a particularly favorable liberation of the
active material. In many cases, sparingly water
10 soluble drugs, which have been dissolved in
polyethylene glycols and then put into soft ~elatin
capsules, are outstanding, by virtue of an
exceptionally good bio-availability of the drug.
From DE-OS 33 07 353 of the applicant,
15 soft gelatin capsules are known in which the dried
capsule shell contains 4 to 40% by weight of
sorbitol and/or sorbitan, the polyethylene glycol
used in the capsule filling for solution and
suspension of the active material is at least 50~
20 by weight of a polyethylene glycol having a mean
molecular weight of 600, and the capsule filling
contains up to 20~ by weight of glycerol and/or
propylene glycol. These soft gelatin capsules have
been remarkably successful, yet they still have the
25 disadvantage that a number of active material~ are
not sufficiently soluble in polyethylene glycol.
Consequently, large capsules are necessary for the
encapsulation of such sparingly soluble active
materials. There exists, therefore, a continuing
30 need for solvents which are able to dissolve larger
amounts of acti~-e materials and yat can be
processed into stable soft gelatin capsules.
Solvents, suitable for human consumption, such as
ethanol, propylene glycol, dimethyl acetamide~
35 lactic acid, glycerol, butanediol, and the

~ ~'7~
polyethylene glycol ethter of tetrahhydrofurfuryl
alcohol, have been shown by the invastigations of
the applicant to be unsuitable for introduction
into soft gelatin capsules in larger quantities,
because the capsule fillings made with these
solvents cause, after a short time, softening and
deformation of the capsules produced, which
therefore are not marketable.
The reasons for these stability problems
are evidetly to be sought in the good water
miscibility and the lower molecular weight of these
solvents.

~'7~5~
SUMMARY OF THE INVENTION
Surprisingl~, it has now been found that
mixtures of polyethylene glycol ethers of
tetrahydrofurfurol are suitable solvents for active
materials in soft gelatin capsules, if the capsule
filling is encapsulated in a wet gelatin shell and
the capsules obtained are intensively dried for at
least 5 days, and preferably for 6 to 10 days.
After 5 to 10 days, the quantities of water which
pass from tha wet gelatin shell into the capsule
filling during encapsulation have obviously been
removed to such an extent that they, together with
the polyethylene glycol ethers of
tetrahydro~urfuryl alcohol, are no longer able,
subsequently, to soften the gelatin shell again and
enable the low molecular weight solvents to escape.
Such a long and intensive drying of soft gelatin
capsules is decidedly unusual; commonly they are
dried for only 1 to 4 days. Longer drying times
not only cause unnecessary costs, but also lead to
an undesirable hardening and embrittlement of the
capsule shell. In the inventive process, certain
amounts of the polyethylene glycol ethers of
tetrahydofurfurol apparently migrate into the
capsule shell and function there as a sotener,
counteracting the hardening and embrittlement of
the capsule shell otherwise observed on drying for
too long. These quantities of the polyethylene
glycol ethers of tetrahydrofurfurol, functioning as
a softener in the capsule shell, also lead,
however, to increased sensitivity of the inventive
capsules to atmospheric moisture, so the finished
capsules should be stored out of contact with
atmospheric moisture. However, capsules

~L27~ 59
-5-
manufactured according to the invention and stored
with atmospheric moisturs excluded have been found
to be still completely stable after 3 years.
For the first time, therefore, the
manufacture of stable soft gelatin capsules with a
low molecular weight organic solvent, mixable with
water in all.proportions, has been successful and a
wide field of possible new applications for this
solvent has been opened up.
DETAILED DESCRIPTION OF ~HE INVENTION
The polyethylene glycol ethers of
tetrahydrofurfurol have the general formula I:
CE~2 - CH2
CH2 ~C CH2(OCH2 ,CH2)nOH
where n = 1 to 6.
In particular, mixtures in which n = 1 to 6 or in
which n = 1 and 2 are commercially available and
suitable for human consumption. Thus, the
commercial products "Glyco~urol 75" (a mixture of
mono- and di-ethylene glycol ethers in a ratio of
approximately 1 : 1, wikh a mean molecular weight
of about 168) and Tetra~lykol ~ (a mixture of
mono-ethylene glycol ether, di-ethylene glycol
ether and variable proportions of tri-, tetra- and
penta-ethylene glycol ethers, with a mean molecular
weight of about 190) are especially suitable~ A
number of sparingly soluble active materials are
substantially more soluble in these sol~ents than
in polyethylene glycol, so that soft gelatin
capsules, according to the invention which axe

lX70t7~9
6 61368-773
substantially smaller and more pleasant to take, may be
manufactured. For example, the ~wo interesting active materials,
diazepam and nifedipine, are practically twice as soluble in the
solvent used according to the invention as in Polyethylenglycol
400.
In addition, it has been found that not only pure
mixtures of polyethylene glycol ethers of tetrahydrofurfuryl
alcohol are suitable, but also mixtures with other customary
solvents and solvent aids. In particular, up to 50% by weight of
lQ polyethylene glycol, with a molecular weight of 30Q to 600 can be
added to the polyethylene glycol ethers of tetrahydrofurfuryl
alcohol ! without changing its solubility for sparingly soluble
active materials ~oo much.
The invention therefore relates to soft gelatin capsules
with a gelatin shell, at least one plasticizer and a capsule
filling that contains at least one pharmacologically active
substance and a solvent, the solvent containing at least 50% by
weight of a mlxture of polyethylene glycol ethers o~
tetrahydrofurfuryl alcohol of the formula I as defined above.
Solvent aids and emulsifiers, which are themselves
soluble, can be added to increase the solubility of certain active
materials in the solvents and solvent mixtures used according to
the invention.
The customary plasticizers, suah as glycerol, sorbitol,
sorbitan etc. are added to the;gelatln shell.

~2'7~)'759
6a 61368-773
In addition, other customary auxiliary agents, such as a
preservative (e.g. p-aminobenzoic acid and potassium sorbate),
dyestuffs, pigments, flavorings or perfumes, can be added to the
capsule shell. Desirably, the finished capsules can subsequently
also be provided with special coatings to facilitate or improve
their application. The polyethylene glycol ethers of
tetrahydrofurfuryl alcohol, used according to the invention, are
pharmacologically and toxicologically unob~ectionable an~ are
already established to a
.: . -
: .

70759
considerable extent for the manufacture ofinjection solutions. In the past, the oral
application of active materials in these solvents
has not occurred because the polyethylene glycol
ethers of tetrahydrofurfuryl alcohol tastes
decidedly unpleasant. A further advantage o~ the
present invention is, therefore, that these good
solvents for many active materials have now also
become available for oral dosage forms. The
relatively small amounts of the solvents in the
capsule shell do not in any way impair the oral
application of the inventive soft gelatin capsules.
The inventive soft gelatin capsules and
the process for their manufacture are explained in
more detail in the following examples and
comparative tests.
EXAMPLE 1
S00 mg of the commercial product
Tetraglykol ~ was first, without ad~ition of
active materials or auxiliary agents, introduced
into soft gelatin capsules which were then dried at
20 degrees C and 20 to 25% relative humidity, some
for only 1 day and some for 3, 5, 8 and 10 days.
After a few weeks, the solvent escaped through the
capsule shell from those capsules that were dried
for only 1 day, so that these capsules were useless
as a commercial product. The capsules that were
dried for 3 days were stable for only 12 months.
The capsules that had been dried according to the
invention for 5, 8 or 10 days were, under the same
storage conditions, completely stable for 3 years.
Also, with 8 and 10 days drying, no embrittlement
took place.

~L2~70~759
-8-
EXAMPLE 2
Comparative solubility investigations of the active
materials nifedipine and diazepam in
polyethylenglycol 400 and Tetraglycol R yielded
the following values, in % by weight, for the
maximum solubility at 21 degrees C:
Active material Diazepam Nifedipine
PEG 400 5.9~ 4O9%
Tetraglyco~ 11.5% 10.2%
The following recipes were prepared, corresponding
to the usual dosages o~ ni~edipine and dia2epam.
The data refer to mg/capsule.
1. Nifedipine 10.0 mg
Tetraglykol~ 110.0 m~
120.0 mg
20 2. Diazepam 5.0 mg
Tetraglykol 115.0 mg
120.0 mg
3. Diazepam ~ 5.0 mg
Tetraglykol 60.0 mg
PEG 400 50.0 mg
Glycerol 5.0 mg
120.0 mg
These solutions of active materials were formed
into oval capsules within the very small, and
therefore readily swallowed, capsule size of 2
minims and dried for 6 days in each case. On
storage, in the absence o~ atmospheric moisture,

~27(~7~9
g_
the capsules were completely stable, like the
capsules without the active material.

Representative Drawing

Sorry, the representative drawing for patent document number 1270759 was not found.

Administrative Status

2024-08-01:As part of the Next Generation Patents (NGP) transition, the Canadian Patents Database (CPD) now contains a more detailed Event History, which replicates the Event Log of our new back-office solution.

Please note that "Inactive:" events refers to events no longer in use in our new back-office solution.

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Event History , Maintenance Fee  and Payment History  should be consulted.

Event History

Description Date
Time Limit for Reversal Expired 2005-06-27
Letter Sent 2004-06-28
Inactive: Late MF processed 1998-09-29
Letter Sent 1998-06-26
Grant by Issuance 1990-06-26

Abandonment History

There is no abandonment history.

Fee History

Fee Type Anniversary Year Due Date Paid Date
MF (category 1, 7th anniv.) - standard 1997-06-26 1997-06-20
MF (category 1, 8th anniv.) - standard 1998-06-26 1998-09-29
Reversal of deemed expiry 1998-06-26 1998-09-29
MF (category 1, 9th anniv.) - standard 1999-06-28 1999-05-03
MF (category 1, 10th anniv.) - standard 2000-06-26 2000-05-18
MF (category 1, 11th anniv.) - standard 2001-06-26 2001-05-16
MF (category 1, 12th anniv.) - standard 2002-06-26 2002-05-31
MF (category 1, 13th anniv.) - standard 2003-06-26 2003-06-03
Owners on Record

Note: Records showing the ownership history in alphabetical order.

Current Owners on Record
R.P. SCHERER CORPORATION
Past Owners on Record
WERNER BROX
WILFRIED GABLER
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.
Documents

To view selected files, please enter reCAPTCHA code :



To view images, click a link in the Document Description column. To download the documents, select one or more checkboxes in the first column and then click the "Download Selected in PDF format (Zip Archive)" or the "Download Selected as Single PDF" button.

List of published and non-published patent-specific documents on the CPD .

If you have any difficulty accessing content, you can call the Client Service Centre at 1-866-997-1936 or send them an e-mail at CIPO Client Service Centre.


Document
Description 
Date
(yyyy-mm-dd) 
Number of pages   Size of Image (KB) 
Claims 1993-09-21 2 43
Abstract 1993-09-21 1 13
Drawings 1993-09-21 1 13
Descriptions 1993-09-21 10 294
Maintenance Fee Notice 1998-07-26 1 179
Late Payment Acknowledgement 1998-10-12 1 171
Maintenance Fee Notice 2004-08-22 1 172
Fees 1996-05-15 1 88
Fees 1994-03-21 1 68
Fees 1995-05-17 1 96
Fees 1993-03-18 1 57
Fees 1992-03-22 1 27